ErbB-2 signaling in advanced prostate cancer progression and potential therapy

Dannah R. Miller, Matthew A. Ingersoll, Ming-Fong Lin

Research output: Contribution to journalReview article

Abstract

Currently, prostate cancer (PCa) remains the most commonly diagnosed solid tumor and the second leading cause of cancer-related deaths in US men. Most of these deaths are attributed to the development of castration-resistant (CR) PCa. ErbB-2 and ErbB family members have been demonstrated to contribute to the progression of this lethal disease. In this review, we focus on updating the role of ErbB-2 in advanced PCa progression and its regulation, including its regulation via ligand activation, miRNAs and protein phosphorylation. We also discuss its downstream signaling pathways, including AKT, ERK1/2 and STATs, involved in advanced PCa progression. Additionally, we evaluate the potential of ErbB-2, focusing on its protein hyper-phosphorylation status, as a biomarker for aggressive PCa as well as the effectiveness of ErbB-2 as a target for the treatment of CR PCa via a multitude of approaches, including orally available inhibitors, intratumoral expression of cPAcP, vaccination and immunotherapy.

Original languageEnglish (US)
Pages (from-to)R195-R209
JournalEndocrine-Related Cancer
Volume26
Issue number4
DOIs
StatePublished - Jan 1 2018

Fingerprint

Prostatic Neoplasms
Castration
Therapeutics
Phosphorylation
MicroRNAs
Immunotherapy
Disease Progression
Neoplasms
Vaccination
Proteins
Biomarkers
Ligands

Keywords

  • Cancer
  • Castration-resistant prostate
  • ErbB-2
  • ErbB-2 regulation
  • ErbB-2-targeting therapies

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research

Cite this

ErbB-2 signaling in advanced prostate cancer progression and potential therapy. / Miller, Dannah R.; Ingersoll, Matthew A.; Lin, Ming-Fong.

In: Endocrine-Related Cancer, Vol. 26, No. 4, 01.01.2018, p. R195-R209.

Research output: Contribution to journalReview article

Miller, Dannah R. ; Ingersoll, Matthew A. ; Lin, Ming-Fong. / ErbB-2 signaling in advanced prostate cancer progression and potential therapy. In: Endocrine-Related Cancer. 2018 ; Vol. 26, No. 4. pp. R195-R209.
@article{f6e9e7f23f5d42b49b6ea9f4b13e171f,
title = "ErbB-2 signaling in advanced prostate cancer progression and potential therapy",
abstract = "Currently, prostate cancer (PCa) remains the most commonly diagnosed solid tumor and the second leading cause of cancer-related deaths in US men. Most of these deaths are attributed to the development of castration-resistant (CR) PCa. ErbB-2 and ErbB family members have been demonstrated to contribute to the progression of this lethal disease. In this review, we focus on updating the role of ErbB-2 in advanced PCa progression and its regulation, including its regulation via ligand activation, miRNAs and protein phosphorylation. We also discuss its downstream signaling pathways, including AKT, ERK1/2 and STATs, involved in advanced PCa progression. Additionally, we evaluate the potential of ErbB-2, focusing on its protein hyper-phosphorylation status, as a biomarker for aggressive PCa as well as the effectiveness of ErbB-2 as a target for the treatment of CR PCa via a multitude of approaches, including orally available inhibitors, intratumoral expression of cPAcP, vaccination and immunotherapy.",
keywords = "Cancer, Castration-resistant prostate, ErbB-2, ErbB-2 regulation, ErbB-2-targeting therapies",
author = "Miller, {Dannah R.} and Ingersoll, {Matthew A.} and Ming-Fong Lin",
year = "2018",
month = "1",
day = "1",
doi = "10.1530/ERC-19-0009",
language = "English (US)",
volume = "26",
pages = "R195--R209",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "Society for Endocrinology",
number = "4",

}

TY - JOUR

T1 - ErbB-2 signaling in advanced prostate cancer progression and potential therapy

AU - Miller, Dannah R.

AU - Ingersoll, Matthew A.

AU - Lin, Ming-Fong

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Currently, prostate cancer (PCa) remains the most commonly diagnosed solid tumor and the second leading cause of cancer-related deaths in US men. Most of these deaths are attributed to the development of castration-resistant (CR) PCa. ErbB-2 and ErbB family members have been demonstrated to contribute to the progression of this lethal disease. In this review, we focus on updating the role of ErbB-2 in advanced PCa progression and its regulation, including its regulation via ligand activation, miRNAs and protein phosphorylation. We also discuss its downstream signaling pathways, including AKT, ERK1/2 and STATs, involved in advanced PCa progression. Additionally, we evaluate the potential of ErbB-2, focusing on its protein hyper-phosphorylation status, as a biomarker for aggressive PCa as well as the effectiveness of ErbB-2 as a target for the treatment of CR PCa via a multitude of approaches, including orally available inhibitors, intratumoral expression of cPAcP, vaccination and immunotherapy.

AB - Currently, prostate cancer (PCa) remains the most commonly diagnosed solid tumor and the second leading cause of cancer-related deaths in US men. Most of these deaths are attributed to the development of castration-resistant (CR) PCa. ErbB-2 and ErbB family members have been demonstrated to contribute to the progression of this lethal disease. In this review, we focus on updating the role of ErbB-2 in advanced PCa progression and its regulation, including its regulation via ligand activation, miRNAs and protein phosphorylation. We also discuss its downstream signaling pathways, including AKT, ERK1/2 and STATs, involved in advanced PCa progression. Additionally, we evaluate the potential of ErbB-2, focusing on its protein hyper-phosphorylation status, as a biomarker for aggressive PCa as well as the effectiveness of ErbB-2 as a target for the treatment of CR PCa via a multitude of approaches, including orally available inhibitors, intratumoral expression of cPAcP, vaccination and immunotherapy.

KW - Cancer

KW - Castration-resistant prostate

KW - ErbB-2

KW - ErbB-2 regulation

KW - ErbB-2-targeting therapies

UR - http://www.scopus.com/inward/record.url?scp=85062809278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062809278&partnerID=8YFLogxK

U2 - 10.1530/ERC-19-0009

DO - 10.1530/ERC-19-0009

M3 - Review article

VL - 26

SP - R195-R209

JO - Endocrine-Related Cancer

JF - Endocrine-Related Cancer

SN - 1351-0088

IS - 4

ER -